Aarti Pharmalabs Ltd (AARTIPHARM) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Standalone revenue slightly decreased YoY, but EBITDA and PAT saw growth.
- Consolidated revenue appears lower YoY due to Ganesh Polyclinic's JV status change, excluding its turnover. However, EBITDA and PAT still include Ganesh Polyclinic's share of profit.
- Aarti USA's revenue declined significantly due to the shift of distribution business to Aarti Industries' US subsidiary.
- Xanthine derivatives contributed 50% of Q1 turnover, API and intermediates 40%, and CDMO/CMO 10%.
- One xanthine derivative plant underwent a planned shutdown and upgrade, partially contributing to the standalone top-line decline.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.